On air · 2 of 3 networks
Houston Methodist
- houstonmethodist.org
- Healthcare & Life Sciences
- US
- 22,515 employees
Houston Methodist’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 707. Watch Houston Methodist with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 706 | Checked 29 Oct 2026 | See all 707 ads → | ||
| Meta | Running | 276 | Active ads on the Meta Ad Library, all countries | Checked 28 Oct 2026 | Collect them with the API → |
| Not checked | — |
Houston Methodist has 706 live LinkedIn ads. Its Facebook page had 276 active ads on 28 Oct 2026, and we recorded 1k+ Google ads on 30 Sept 2026.
Latest ads
- LINKEDIN · JOBSince 6 Jan 2025
- LINKEDIN · VIDEORecorded 23 Sept 2026
Houston Methodist is at the forefront of a groundbreaking clinical trial aimed at improving outcomes for hemodialysis patients requiring arteriovenous fistulas (AVFs). The SAVE Fistulas trial, a first-of-its-kind randomized controlled study, is evaluating VenoStent's SelfWrap, a bioabsorbable wrap designed to improve the success rate of fistulas in patients with chronic kidney disease (CKD). The objective of this 200-patient trial is to reduce the nearly 60% AVF failure rate.
- LINKEDIN · IMAGERecorded 23 Sept 2026
The objective of the SAVE Fistulas trial, a 200-patient randomized controlled study, is to reduce the nearly 60% arteriovenous fistula (AVF) failure rate in patients with chronic kidney disease (CKD) by lending structural support to the vein. "If we can reduce the failure rate from 60% to 30%, that would be a major step forward for patients," said Eric Peden, MD, chief of vascular surgery at Houston Methodist Hospital and co-national PI of the trial.
- LINKEDIN · VIDEORecorded 23 Sept 2026
"This is a patient group with historically poor outcomes, and we need innovation to change that,” said Eric Peden, MD, chief of vascular surgery at Houston Methodist Hospital and co-national PI of the SAVE Fistulas trial. The objective of this 200-patient randomized controlled trial is to reduce the nearly 60% arteriovenous fistula (AVF) failure rate in patients with chronic kidney disease (CKD).
- LINKEDIN · IMAGERecorded 23 Sept 2026
"This is a patient group with historically poor outcomes, and we need innovation to change that,” said Eric Peden, MD, chief of vascular surgery at Houston Methodist Hospital and co-national PI of the SAVE Fistulas trial. The objective of this 200-patient randomized controlled trial is to reduce the nearly 60% arteriovenous fistula (AVF) failure rate in patients with chronic kidney disease (CKD).
- LINKEDIN · IMAGERecorded 23 Sept 2026
A groundbreaking piece published in Nature Reviews Gastroenterology & Hepatology and co-authored by Houston Methodist gastroenterologist Eamonn Quigley, MD, offers clear, evidence-based corrections to common misconceptions that often lead to misdiagnosis, unnecessary testing and suboptimal treatment of irritable bowel syndrome (IBS).
6 of 707 adsSign up to see every Houston Methodist ad, filter by format and date, and get alerts on new ones.
See all 707 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.